Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year. During that time, I've had the pleasure and the privilege of working with our investor relations team, usually behind the scenes of these earning calls. And so it's exciting to be supporting you today in this more front-facing role. I'm joined by Jason Kelly, our co-founder and CEO, and Mark Dimitrick, our CFO. Thanks as always for joining us. We're really looking forward to updating you on our progress today. As a reminder, during the presentation today, we will be making forward-looking statements. These involve risks and uncertainties. So please refer to our filings with the SEC to learn more about these risks and uncertainties, including in our most recent 10-K. Today, in addition to updating you on the quarter and the full year results, we're going to provide updates on our path towards adjusted EBITDA breakeven, as well as customer progress in our cell engineering business across both our services and tools offerings. and the latest offerings in our biosecurity business. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors, and the public. You can submit questions for that to us in advance via X. Please tag your post with the hashtag GinkgoResults, or email us, our inbox is investors at ginkgobioworks.com. I'll be checking that throughout the call. All right. Over to you, Jason. Thanks, Joseph. And thanks, everyone, for joining us. We always start with our mission of making biology easier to engineer. And similar to last quarter, our focus for that mission is on these three key objectives. First, we want to reach adjusted EBITDA breakeven while maintaining a cash margin of safety. And we ended this quar...